Pfizer, Starboard
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,
RSV, Pfizer
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...
Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...
With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...
19h
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback